{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:12:32Z","timestamp":1760001152280,"version":"build-2065373602"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["FKZ 01EX1015B"],"award-info":[{"award-number":["FKZ 01EX1015B"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.jpba.2012.07.025","type":"journal-article","created":{"date-parts":[[2012,7,31]],"date-time":"2012-07-31T06:01:57Z","timestamp":1343714517000},"page":"63-70","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Analysis of total and unbound hydromorphone in human plasma by ultrafiltration and LC\u2013MS\/MS: Application to clinical trial in patients undergoing open heart surgery"],"prefix":"10.1016","volume":"71","author":[{"given":"Teijo I.","family":"Saari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg","family":"Fechner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Ihmsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Sch\u00fcttler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Jeleazcov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2012.07.025_bib0005","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jpba.2011.11.012","article-title":"Determination of hydromorphone in human plasma by a sensitive RP-HPLC\u2013ESI-MS method and its application to a clinical pharmacokinetic study in postoperative patients after low dose intravenous administration with infusion pump","volume":"61","author":"Sun","year":"2012","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2012.07.025_bib0010","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1002\/jps.21916","article-title":"Significance of protein binding in pharmacokinetics and pharmacodynamics","volume":"99","author":"Schmidt","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2012.07.025_bib0015","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0304-3959(97)03336-8","article-title":"Hydromorphone analgesia after intravenous bolus administration","volume":"71","author":"Coda","year":"1997","journal-title":"Pain"},{"key":"10.1016\/j.jpba.2012.07.025_bib0020","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1213\/ane.0b013e3181823efb","article-title":"The side effects of morphine and hydromorphone patient-controlled analgesia","volume":"107","author":"Hong","year":"2008","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.jpba.2012.07.025_bib0025","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1007\/s001010100206","article-title":"Postoperative pain therapy with hydromorphone and metamizole. A prospective randomized study in intravenous patient-controlled analgesia (PCA)","volume":"50","author":"Lehmann","year":"2001","journal-title":"Anaesthesist"},{"key":"10.1016\/j.jpba.2012.07.025_bib0030","first-page":"84","article-title":"Hydromorphone: pharmacology and clinical applications in cancer patients","volume":"9","author":"Sarhill","year":"2001","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.jpba.2012.07.025_bib0035","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/clpt.1988.167","article-title":"Hydromorphone levels and pain control in patients with severe chronic pain","volume":"44","author":"Reidenberg","year":"1988","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jpba.2012.07.025_bib0040","unstructured":"Supervisor's Secondary Review, Pharmacology\/Toxicology Review and Evaluation, Application No. 21-217s000, EXALGO (hydromorphone hydrochloride) extended release tablets, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, May 22, 2009. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2010\/021217s000PharmR.pdf (accessed 15.07.12)."},{"key":"10.1016\/j.jpba.2012.07.025_bib0045","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/AJP.0b013e318122d1e4","article-title":"Enhanced postoperative sensitivity to painful pressure stimulation after intraoperative high dose remifentanil in patients without significant surgical site pain","volume":"23","author":"Schmidt","year":"2007","journal-title":"Clin. J. Pain"},{"key":"10.1016\/j.jpba.2012.07.025_bib0050","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2165\/00003088-199630060-00003","article-title":"Measurement and analysis of unbound drug concentrations","volume":"30","author":"Wright","year":"1996","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jpba.2012.07.025_bib0055","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1097\/00000542-199512000-00010","article-title":"Linearity of pharmacokinetics and model estimation of sufentanil","volume":"83","author":"Gepts","year":"1995","journal-title":"Anesthesiology"},{"key":"10.1016\/j.jpba.2012.07.025_bib0060","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/clpt.2008.80","article-title":"Pharmacokinetics and pharmacodynamics of intravenously administered anesthetic drugs: concepts and lessons for drug development","volume":"84","author":"Kern","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jpba.2012.07.025_bib0065","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/bja\/aeg263","article-title":"Influence of peroperative opioid on postoperative pain after major abdominal surgery: sufentanil TCI versus remifentanil TCI. A randomized, controlled study","volume":"91","author":"Derrode","year":"2003","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.jpba.2012.07.025_bib0070","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/bja\/aer108","article-title":"Optimizing intravenous drug administration by applying pharmacokinetic\/pharmacodynamic concepts","volume":"107","author":"Struys","year":"2011","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.jpba.2012.07.025_bib0075","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1053\/j.jvca.2011.03.185","article-title":"Target-controlled dosing of remifentanil during cardiac surgery reduces postoperative hyperalgesia","volume":"25","author":"Richebe","year":"2011","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"key":"10.1016\/j.jpba.2012.07.025_bib0080","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1093\/bja\/80.6.748","article-title":"Patient-maintained analgesia with target-controlled alfentanil infusion after cardiac surgery: a comparison with morphine PCA","volume":"80","author":"Checketts","year":"1998","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.jpba.2012.07.025_bib0085","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1093\/bja\/aer041","article-title":"Remifentanil patient-controlled analgesia effect-site target-controlled infusion compared with morphine patient-controlled analgesia for treatment of acute pain after uterine artery embolization","volume":"106","author":"Lipszyc","year":"2011","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.jpba.2012.07.025_bib0090","unstructured":"J. Fechner, H., Ihmsen, J. Sch\u00fcttler, C. Jeleazcov, The impact of intraoperative sufentanil dosing on postoperative pain, hyperalgesia and morphine consumption after cardiac surgery, Eur. J. Pain, in press."},{"key":"10.1016\/j.jpba.2012.07.025_bib0095","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jpba.2012.03.050","article-title":"Determination of total and unbound sufentanil in human plasma by ultrafiltration and LC\u2013MS\/MS: application to clinical pharmacokinetic study","volume":"66","author":"Saari","year":"2012","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2012.07.025_bib0100","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jchromb.2005.05.037","article-title":"Improving LC\u2013MS sensitivity through increases in chromatographic performance: comparisons of UPLC-ES\/MS\/MS to HPLC-ES\/MS\/MS","volume":"825","author":"Churchwell","year":"2005","journal-title":"J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci."},{"year":"2001","series-title":"Guidance for Industry, Bioanalytical Method Validation","key":"10.1016\/j.jpba.2012.07.025_bib0105"},{"key":"10.1016\/j.jpba.2012.07.025_bib0110","unstructured":"Millipore Corporation, Centrifree Ultrafiltration Devices, Package Insert. www.millipore.com (accessed 28.06.12)."},{"key":"10.1016\/j.jpba.2012.07.025_bib0115","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/bmc.1088","article-title":"HPLC-UV assay for monitoring total and unbound mycophenolic acid concentrations in children","volume":"23","author":"Zeng","year":"2009","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jpba.2012.07.025_bib0120","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/jat\/34.3.135","article-title":"Determination of moxifloxacin in human plasma, plasma ultrafiltrate, and cerebrospinal fluid by a rapid and simple liquid chromatography\u2013tandem mass spectrometry method","volume":"34","author":"Pranger","year":"2010","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.jpba.2012.07.025_bib0125","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jchromb.2011.11.033","article-title":"Enantioselective analysis of unbound tramadol, O-desmethyltramadol and N-desmethyltramadol in plasma by ultrafiltration and LC\u2013MS\/MS: application to clinical pharmacokinetics","volume":"880","author":"de Moraes","year":"2012","journal-title":"J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2012.07.025_bib0130","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jpba.2010.11.016","article-title":"Rapid UPLC\u2013MS\/MS method for the determination of sufentanil in human plasma and its application in target-controlled infusion system","volume":"54","author":"Liang","year":"2011","journal-title":"J. Pharm. Biomed. Anal."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708512004311?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708512004311?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T08:49:11Z","timestamp":1759999751000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708512004311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":26,"alternative-id":["S0731708512004311"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2012.07.025","relation":{},"ISSN":["0731-7085"],"issn-type":[{"type":"print","value":"0731-7085"}],"subject":[],"published":{"date-parts":[[2012,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of total and unbound hydromorphone in human plasma by ultrafiltration and LC\u2013MS\/MS: Application to clinical trial in patients undergoing open heart surgery","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2012.07.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}